enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. 2025 ICD-10-CM Diagnosis Code Z12.5 - The Web's Free 2023 ICD-10...

    www.icd10data.com/ICD10CM/Codes/Z00-Z99/Z00-Z13/Z12-/Z12.5

    ICD 10 code for Encounter for screening for malignant neoplasm of prostate. Get free rules, notes, crosswalks, synonyms, history for ICD-10 code Z12.5.

  3. Coding Tips for Prostate Cancer Screening-Diagnosis-Treatments

    aihc-assn.org/coding-tips-for-prostate-cancer-screening-diagnosis-and-treatments

    The ICD-10-CM code to use for annual screening services is Z12.5, Encounter for screening for malignant neoplasm of prostate. Codes in the Z12 category have a “Use additional code” instruction if there is family history of the disease.

  4. Z12.5 is a billable diagnosis code used to specify a medical diagnosis of encounter for screening for malignant neoplasm of prostate. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2024 through September 30, 2025.

  5. Prostate Specific Antigen - Quest Diagnostics

    www.questdiagnostics.com/content/dam/corporate/restricted/documents/mlcp/mlcp/...

    Prostate Specific Antigen (PSA), a tumor marker for adenocarcinoma of the prostate, can predict residual tumor in the post-operative phase of prostate cancer. Three to 6 months after radical prostatectomy, PSA is reported to provide a sensitive indicator of persistent disease.

  6. Screening methods for prostate cancer include digital rectal examination (DRE), prostate-specific antigen (PSA) testing, or a combination of both. The code should not be used for diagnostic evaluations or follow-up of confirmed prostate cancer cases. Yes, the Z12.5 code is billable.

  7. Coding Prostate Cancer Screening - AAPC Knowledge Center

    www.aapc.com/blog/48748-coding-prostate-cancer-screening

    The ICD-10 diagnosis code to support either screening is Z12.5 Encounter for screening for malignant neoplasm of prostate. There is no deductible or coinsurance/co-payment for the PSA test, but there is for the screening DRE under Medicare Part B.

  8. Z12.5 is a valid billable ICD-10 diagnosis code for Encounter for screening for malignant neoplasm of prostate. It is found in the 2025 version of the ICD-10 Clinical Modification (CM) and can be used in all HIPAA-covered transactions from Oct 01, 2024 - Sep 30, 2025 .

  9. ICD-10 code Z12.5 for Encounter for screening for malignant neoplasm of prostate is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .

  10. Elevated prostate specific antigen [PSA] 2016 2017 - Converted to Parent Code 2018 2019 2020 2021 2022 2023 2024 2025 Non-Billable/Non-Specific Code ICD-10-CM Diagnosis Code Z13.1

  11. Z12.5 is a billable ICD code used to specify a diagnosis of encounter for screening for malignant neoplasm of prostate. A 'billable code' is detailed enough to be used to specify a medical diagnosis.